RMR Wealth Builders Acquires 593 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• RMR Wealth Builders increased its holdings in Regeneron Pharmaceuticals by 27.7%, acquiring an additional 593 shares and bringing its total to 2,734 shares valued at approximately $1.4 million.
• Regeneron recently reported a quarterly EPS of $12.89, exceeding estimates by $4.46, with revenue of $3.68 billion for the quarter, reflecting a 3.6% year-over-year increase.
• The company announced a quarterly dividend of $0.88 per share, resulting in an annualized dividend yield of 0.6%, with a payout ratio of 8.87%.

RMR Wealth Builders increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 27.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,734 shares of the biopharmaceutical company's stock after buying an additional 593 shares during the quarter. RMR Wealth Builders' holdings in Regeneron Pharmaceuticals were worth $1,435,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. GuoLine Advisory Pte Ltd raised its position in Regeneron Pharmaceuticals by 19.5% in the second quarter. GuoLine Advisory Pte Ltd now owns 67,300 shares of the biopharmaceutical company's stock valued at $35,332,000 after purchasing an additional 11,000 shares during the last quarter. Jacobs & Co. CA increased its stake in shares of Regeneron Pharmaceuticals by 2.4% in the second quarter. Jacobs & Co. CA now owns 10,294 shares of the biopharmaceutical company's stock valued at $5,404,000 after buying an additional 244 shares during the period. Central Pacific Bank Trust Division increased its stake in shares of Regeneron Pharmaceuticals by 70.9% in the second quarter. Central Pacific Bank Trust Division now owns 1,157 shares of the biopharmaceutical company's stock valued at $607,000 after buying an additional 480 shares during the period. AG2R LA Mondiale Gestion D Actifs acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $2,604,000. Finally, Swedbank AB increased its stake in shares of Regeneron Pharmaceuticals by 25.4% in the first quarter. Swedbank AB now owns 223,788 shares of the biopharmaceutical company's stock valued at $141,933,000 after buying an additional 45,297 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 1.4%

Shares of NASDAQ:REGN opened at $560.00 on Monday. The business's 50 day simple moving average is $564.61 and its two-hundred day simple moving average is $577.91. The firm has a market cap of $59.35 billion, a P/E ratio of 14.11, a PEG ratio of 1.87 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,170.58.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company's quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $11.56 earnings per share. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on REGN shares. Redburn Atlantic raised Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Citigroup reaffirmed a "buy" rating and set a $650.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Truist Financial decreased their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Royal Bank Of Canada raised their target price on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research note on Monday, August 4th. Finally, Argus cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.